Spark Therapeutics Inc.'s pleasing phase III top-line data with its compound for blindness-causing, RPE65-mediated, inherited retinal dystrophies (IRDs) whetted investor appetite for more-detailed results and sent hope surging through the sector, as SPK-RPE65 could become the first gene therapy cleared for marketing in the U.S.